Compare Regeneron Pharmaceuticals Inc (REGN) vs Range Resources Corporation Common Stock (RRC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Range Resources Corporation Common Stock — how do they compare? Regeneron Pharmaceuticals Inc trades at $786.71 (market cap $77.54B), while Range Resources Corporation Common Stock trades at $41.78 (market cap $9.93B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 7.8× Range Resources Corporation Common Stock's market cap, and Range Resources Corporation Common Stock pays the higher dividend (0.94%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Range Resources Corporation Common Stock for 0 Days on average.
| REGN | RRC | |
|---|---|---|
Market Cap | $77.54B | $9.93B |
Volume | 629,519 | 2,413,752 |
Sector | Health | Energy |
52-Week High | $852.03 | $47.65 |
52-Week Low | $569.17 | $33.43 |
Typical Hold Time | 107 Days | 0 Days |
Enterprise Value | $72.25B | $10.94B |
Dividend Yield | 0.5% | 0.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $778.36, up 2.04% on the day, with a bullish technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent news highlights a significant expansion of its immunology alliance with Sanofi, valued up to $8 billion, which could drive future growth. Valuation ratios appear reasonable, with a P/E of 18.64 and robust profitability margins.
The outlook for REGN is positive, supported by strong earnings momentum, a lucrative partnership expansion, and a unanimous analyst buy consensus. Key risks include competitive pressures in the biopharma space and reliance on key drug performance. The stock presents a compelling opportunity for growth investors, with a consensus price target of $849.84 suggesting upside potential.
Range Resources (RRC) trades at $42.48, up 2.56% today, with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows solid fundamentals with a P/E of 11.73 and net income margin of 26.32%, while technical indicators signal neutral momentum near key resistance at $43. Recent institutional buying and positive analyst coverage (38.71% buy ratings) support the bullish case.
Outlook remains positive with Q3 2026 earnings expected at $0.776 per share and consensus price target of $44.00 offering 3.6% upside. Risks include energy price volatility and negative net cash flow of -$304M in 2025, though improved 2026 projections show operating cash flow growth to $1.4B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Range Resources Corporation Common Stock
Range Resources Corporation is an independent natural gas and natural gas liquids producer operating in the Appalachian Basin, primarily the Marcellus Shale in Pennsylvania, handling drilling, completion, and gathering and transportation connections for its production.
Read more on RRC →
